Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ronald C. Chen, Gina L. Mazza, Briant Fruth, Han Xiao, Joel Picus, Mary Ellen Taplin, Tanya B. Dorff, Leonard Joseph Appleman, Douglas Jay Weckstein, Akash Patnaik, Alan Haruo Bryce, Daniel Shevrin, James L. Mohler, Daniel M. Anderson, Arpit Rao, Alan Tan, Charles J. Ryan, Scott Eggener, Michael J. Morris, Rahul Raj Aggarwal
Institutions: University of Kansas Medical Center, Mayo Clinic Hospital, Mayo Clinic, Mayo Clinic Comprehensive Cancer Center (Minnesota), Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Dana-Farber Cancer Institute, City Of Hope National Medical Center, University of Pittsburgh, University of Chicago, Endeavor Health, Roswell Park Comprehensive Cancer Center, HealthPartners, Baylor College of Medicine, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Minnesota, University of California, San Francisco
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399394492